Philadelphia-based Passage Bio trims workforce by 23% - Philadelphia Business Journal
IPO Update: Passage Bio Finalizes $126 Million IPO Plan (NASDAQ:PASG) | Seeking Alpha
Philadelphia gene therapy developer Passage Bio set to go public this week - Philadelphia Business Journal
IPO Roundup: Passage Bio Inc, Zhongchao Inc
Here's Why Shares of Passage Bio Dropped Today | The Motley Fool
Covid-19 stalls biotech flotations | Evaluate
Biotech IPOs 2020 and M&A Trends
IPO Update: Passage Bio Finalizes $126 Million IPO Plan (NASDAQ:PASG) | Seeking Alpha
Xconomy: Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic
Philadelphia gene therapy developer Passage Bio set to go public this week - Philadelphia Business Journal
Passage Bio expands its R&D alliance and exclusive licensing relationship with Penn after its record-setting IPO - Penn Center for Innovation
Passage Bio | Fierce Biotech
Passage Bio IPO - Investing Pre-IPO
As Genetics Firm Passage Bio Goes Public, Here Are The Investors Who Stand To Gain — Or Lose — The Most | CB Insights Research
Passage Bio - Org Chart, Teams, Culture & Jobs | The Org
Passage Bio went public during the stock market's worst week since 2008
Passage Bio Announces Pricing of Initial Public Offering
IPO Passage Bio (PASG): обзор компании / Стоит ли инвестировать? - YouTube
Passage Bio
Passage Bio - Funding, Financials, Valuation & Investors
Passage Bio pulls off $216M IPO, blowing past original goal | Fierce Biotech
Simona King, CPA, MBA - Chief Financial Officer - Passage Bio | LinkedIn
Final tally for Philadelphia-based Passage Bio's IPO: $248.4M - Philadelphia Business Journal
Despite Market Drama, Passage Bio Launches $216 Million IPO – PharmaLive
